Al-Dawaa Medical Services Company (4163.SR)
SAR 67.6
(-0.73%)
SAR 67.6
(-0.73%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 2.06 Billion SAR | 4.31% |
| 2022 | 2.01 Billion SAR | 6.61% |
| 2021 | 1.89 Billion SAR | 20.5% |
| 2020 | 1.57 Billion SAR | 0.97% |
| 2019 | 1.55 Billion SAR | 7.67% |
| 2018 | 1.44 Billion SAR | 12.3% |
| 2017 | 1.28 Billion SAR | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 564.42 Million SAR | 7.49% |
| 2024 Q2 | 575.97 Million SAR | 2.05% |
| 2023 Q2 | 525.64 Million SAR | -1.74% |
| 2023 Q1 | 534.97 Million SAR | 0.24% |
| 2023 FY | 2.1 Billion SAR | 4.31% |
| 2023 Q4 | 525.08 Million SAR | 0.8% |
| 2023 Q3 | 520.91 Million SAR | -0.9% |
| 2022 Q4 | 533.69 Million SAR | 10.05% |
| 2022 Q3 | 484.94 Million SAR | -4.31% |
| 2022 Q2 | 506.78 Million SAR | 2.55% |
| 2022 Q1 | 494.17 Million SAR | -7.3% |
| 2022 FY | 2.01 Billion SAR | 6.61% |
| 2021 Q3 | 451.38 Million SAR | -1.44% |
| 2021 Q2 | 457.97 Million SAR | 1.33% |
| 2021 Q4 | 533.08 Million SAR | 18.1% |
| 2021 FY | 1.89 Billion SAR | 20.5% |
| 2021 Q1 | 451.95 Million SAR | 3.42% |
| 2020 Q2 | 530.76 Million SAR | 8.64% |
| 2020 FY | 1.57 Billion SAR | 0.97% |
| 2020 Q4 | 437.03 Million SAR | 0.0% |
| 2020 Q3 | 437.03 Million SAR | -17.66% |
| 2020 Q1 | 488.54 Million SAR | 0.0% |
| 2019 FY | 1.55 Billion SAR | 7.67% |
| 2018 FY | 1.44 Billion SAR | 12.3% |
| 2017 FY | 1.28 Billion SAR | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Middle East Pharmaceutical Industries Co. | 207.04 Million SAR | -897.217% |
| Nahdi Medical Company | 3.52 Billion SAR | 41.381% |
| Al-Razi Medical Co. | 14.07 Million SAR | -14570.406% |
| Almujtama Alraida Medical Co. | 129.2 Million SAR | -1497.981% |